IFN-alpha has been used successfully for the treatment of cutaneous T-cell lymphoma for many years and it remains an indispensable drug for this condition. Its antiproliferative and immunomodulatory properties are used in the treatment of this disease. According to the current guidelines for the treatment of cutaneous T-cell lymphoma, it is considered as the first-line drug for stages IIB and III, where it is often administered concomitantly with systemic PUVA and retinoids. As monotherapy, it is recommended in stages IA and IIA, if skin directed therapies are not effective. As a maintenance therapy with low dosages, it is associated with prolongation of the duration of remissions. Optimal treatment regimen is adjusted individually, according to the stage of disease, dissemination of skin lesions and the patient's tolerance for IFN. Several acute and chronic side effects can occur during the treatment with IFN-alpha, which are dose-related, predictable and often reversible.Interferon alfa se že mnogo let uspešno uporablja za zdravljenje kožnih T-celičnih limfomov in je za to bolezen še vedno nepogrešljivo zdravilo. Pri kožnih limfomih izkoriščamo predvsem njegovo antiproliferativno in imunomodulatorno delovanje. V sodobnih smernicah za zdravljenje kožnih T-celičnih limfomov je zdravilo izbire v stadijih IIB in III, kjer se pogosto uporablja v kombinaciji s sistemsko PUVA ali s sistemskim retinoidom. V monoterapiji se priporoča v stadijih IA do IIA, kadar so izčrpane lokalne možnosti zdravljenja. Kot vzdrževalno zdravljenje v manjših odmerkih pomembno podaljša remisijo. Režim zdravljenja prilagajamo individualno, glede na stadij bolezni, razširjenost kožnih sprememb in bolnikovo odzivnost na zdravilo. Zdravljenje je povezano z nekaterimi akutnimi in kroničnimi neželenimi sopojavi, ki so pogostejši pri večjih odmerkih, vendar so predvidljivi in praviloma reverzibilni
